This Study Collects Information on the Safety of Inhaled Pegylated Adrenomedullin (PEG-ADM), How the Drug is Tolerated and How it Affects Patients Suffering From a Type of Lung Failure That Cause Fluid to Build up in the Lungs Making Breathing Difficult (ARDS)

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Terminated (based on Part A results, Bayer decided to not continue investigating BAY 1097761 further in Part B; this was not due to any safety data for BAY 1097761)

Conditions

Acute Respiratory Distress Syndrome

Interventions

DRUG: BAY1097761 Active Dose 1
OTHER: Placebo to BAY1097761
DRUG: BAY1097761 Active Dose 2

Sponsor

Bayer